{"id":3720,"date":"2020-10-01T11:57:03","date_gmt":"2020-10-01T09:57:03","guid":{"rendered":"https:\/\/www.ab-science.com\/maladie-dalzheimer\/"},"modified":"2026-09-29T10:32:54","modified_gmt":"2026-09-29T08:32:54","slug":"maladie-alzheimer","status":"publish","type":"page","link":"https:\/\/ab-science.excalibra.com\/fr\/pipeline\/masitinib-apercu\/maladie-alzheimer\/","title":{"rendered":"Maladie d’Alzheimer"},"content":{"rendered":"

[vc_row][vc_column]

<\/span>\u00c0 propos de la maladie d'Alzheimer<\/span><\/div><\/div>
<\/div>[vc_column_text]La maladie d’Alzheimer est un trouble neurod\u00e9g\u00e9n\u00e9ratif irr\u00e9versible qui entra\u00eene une alt\u00e9ration invalidante de la m\u00e9moire et des capacit\u00e9s cognitives. La maladie d’Alzheimer est la cause la plus fr\u00e9quente de d\u00e9mence chez les personnes \u00e2g\u00e9es. Le masitinib est actuellement \u00e9tudi\u00e9 dans les formes l\u00e9g\u00e8res \u00e0 mod\u00e9r\u00e9es de la maladie d’Alzheimer.<\/p>\n

Actuellement, il n’existe pas de traitement satisfaisant pour les formes l\u00e9g\u00e8res et mod\u00e9r\u00e9es de la maladie d’Alzheimer. Il s’agit donc d’un domaine o\u00f9 les besoins m\u00e9dicaux restent tr\u00e8s importants et non satisfaits.[\/vc_column_text]

<\/span>Le positionnement du masitinib dans la maladie d'Alzheimer<\/span><\/div><\/div>
<\/div>[vc_column_text]Le masitinib est positionn\u00e9 dans le traitement de la maladie d’Alzheimer l\u00e9g\u00e8re et mod\u00e9r\u00e9e, c’est-\u00e0-dire pour les patients pr\u00e9sentant d\u00e9j\u00e0 des signes cliniques de d\u00e9mence. Le masitinib n’est pas positionn\u00e9 dans les formes prodromiques (pr\u00e9-symptomatiques) de la maladie.<\/p>\n

La justification de l’\u00e9valuation du masitinib dans la maladie d’Alzheimer est bas\u00e9e sur l’inhibition par le masitinib des kinases c-Kit, Lyn, Fyn et CSF1R.[\/vc_column_text]

<\/div>
<\/span>R\u00e9sultats positifs de phase 2 avec le masitinib dans la maladie d'Alzheimer<\/span><\/div><\/div>
<\/div>[vc_column_text]AB Science a rapport\u00e9 des r\u00e9sultats positifs d\u2019une \u00e9tude de preuve de concept de phase 2A avec le masitinib dans la maladie d\u2019Alzheimer. Dans cette \u00e9tude, le masitinib a montr\u00e9 une diminution du d\u00e9clin de la fonction cognitive et une am\u00e9lioration des activit\u00e9s de la vie quotidienne. Les r\u00e9sultats de l’\u00e9tude ont \u00e9t\u00e9 publi\u00e9s<\/a> dans Alzheimer\u2019s Research & Therapy.[\/vc_column_text]
<\/span>R\u00e9sultats positifs de phase 2B\/3 avec le masitinib dans la maladie d'Alzheimer<\/span><\/div><\/div>
<\/div>[vc_column_text]AB Science a termin\u00e9 une \u00e9tude de phase 2B\/3 pour \u00e9valuer la s\u00e9curit\u00e9 et l\u2019efficacit\u00e9 du masitinib chez les patients atteints d\u2019une maladie d\u2019Alzheimer l\u00e9g\u00e8re \u00e0 mod\u00e9r\u00e9e confirm\u00e9e. Dans cette \u00e9tude, le masitinib a \u00e9t\u00e9 administr\u00e9 en compl\u00e9ment d\u2019un inhibiteur de la cholinest\u00e9rase (don\u00e9p\u00e9zil, rivastigmine ou galantamine) et\/ou de la m\u00e9mantine.<\/p>\n

L\u2019\u00e9tude a d\u00e9montr\u00e9 que le masitinib \u00e0 la dose de 4,5 mg\/kg\/jour a g\u00e9n\u00e9r\u00e9 un effet de traitement significatif par rapport au bras contr\u00f4le sur le crit\u00e8re d\u2019\u00e9valuation principal, la variation du score ADAS-Cog par rapport \u00e0 l\u2019inclusion, instrument qui mesure l\u2019effet sur la cognition et la m\u00e9moire (p\u00a0=\u00a00,0003).<\/p>\n

L\u2019\u00e9tude a \u00e9galement d\u00e9montr\u00e9 que le masitinib \u00e0 la dose de 4,5 mg\/kg\/jour a g\u00e9n\u00e9r\u00e9 une am\u00e9lioration du score ADCS-ADL par rapport \u00e0 l\u2019inclusion (p = 0,0381), ce crit\u00e8re n\u2019atteignant toutefois pas le seuil de signification pr\u00e9sp\u00e9cifi\u00e9 de 2,5 %. Le score ADCS-ADL (Alzheimer\u2019s Disease Cooperative Study Activities of Daily Living) \u00e9value l\u2019autonomie et les activit\u00e9s de la vie quotidienne.<\/p>\n

Il y avait significativement moins de patients atteignant le stade de d\u00e9mence s\u00e9v\u00e8re (MMSE < 10) avec le masitinib \u00e0 la dose de 4,5 mg\/kg\/jour compar\u00e9 au placebo apr\u00e8s 24 semaines de traitement (p\u00a0=\u00a00,0446).<\/p>\n

La tol\u00e9rance du masitinib \u00e0 la dose de 4,5 mg\/kg\/jour \u00e9tait acceptable et conforme \u00e0 son profil de risque connu.<\/p>\n

R\u00e9f\u00e9rence : Dubois B, et al. Masitinib for mild-to-moderate Alzheimer\u2019s disease: results from a randomized, placebo-controlled, phase 3, clinical trial<\/a>. Alzheimer\u2019s Research & Therapy. 2023;15:39. Erratum<\/a> : 2023;15:85.[\/vc_column_text]

<\/span>\u00c9tude confirmatoire de phase 3 avec le masitinib dans le traitement de la maladie d'Alzheimer l\u00e9g\u00e8re<\/span><\/div><\/div>
<\/div>[vc_column_text]<\/p>\n

AB Science entend initier une \u00e9tude confirmatoire de phase 3 \u00e9valuant le masitinib chez les patients atteints de la maladie d\u2019Alzheimer l\u00e9g\u00e8re. L\u2019\u00e9tude doit recruter 600 patients dont le diagnostic clinique de maladie d\u2019Alzheimer l\u00e9g\u00e8re a \u00e9t\u00e9 confirm\u00e9, ce qui correspond \u00e0 un score d\u2019activit\u00e9s de la vie quotidienne (ADCS-ADL) inf\u00e9rieur \u00e0 73 et \u00e0 un score MMSE compris entre 21 et 25, inclus. L\u2019objectif de l\u2019\u00e9tude AB21004 est de confirmer l\u2019effet du traitement par le masitinib \u00e0 la dose de 4,5 mg\/kg\/jour en compl\u00e9ment d\u2019un inhibiteur de la cholinest\u00e9rase et\/ou de la m\u00e9mantine chez les patients atteints de la maladie d\u2019Alzheimer \u00e0 un stade l\u00e9ger. Le crit\u00e8re d\u2019\u00e9valuation principal sera la variation absolue du score iADRS \u00e0 la semaine 24 par rapport \u00e0 l\u2019inclusion, l\u2019ADAS-Cog-11 et l\u2019ADCS-ADL figurant parmi les crit\u00e8res secondaires.<\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_column_text]La maladie d’Alzheimer est un trouble neurod\u00e9g\u00e9n\u00e9ratif irr\u00e9versible qui entra\u00eene une alt\u00e9ration invalidante de la m\u00e9moire et des capacit\u00e9s cognitives. La maladie d’Alzheimer est la cause la plus fr\u00e9quente de d\u00e9mence chez les personnes \u00e2g\u00e9es. Le masitinib est actuellement \u00e9tudi\u00e9 dans les formes l\u00e9g\u00e8res \u00e0 mod\u00e9r\u00e9es de la maladie d’Alzheimer. Actuellement, il n’existe pas de…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":3763,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3720","page","type-page","status-publish","hentry","description-off"],"yoast_head":"\nTraitement de la maladie d'Alzheimer l\u00e9g\u00e8re et mod\u00e9r\u00e9e avec le masitinib<\/title>\n<meta name=\"description\" content=\"Le masitinib est positionn\u00e9 dans le traitement de la maladie d'Alzheimer l\u00e9g\u00e8re et mod\u00e9r\u00e9e, pour les patients pr\u00e9sentant des signes de d\u00e9mence\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Maladie d'Alzheimer\" \/>\n<meta property=\"og:description\" content=\"Le masitinib est positionn\u00e9 dans le traitement de la maladie d'Alzheimer l\u00e9g\u00e8re et mod\u00e9r\u00e9e, pour les patients pr\u00e9sentant des signes de d\u00e9mence\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ab-science.excalibra.com\/fr\/pipeline\/masitinib-apercu\/maladie-alzheimer\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-29T08:32:54+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/maladie-alzheimer\\\/\",\"url\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/maladie-alzheimer\\\/\",\"name\":\"Traitement de la maladie d'Alzheimer l\u00e9g\u00e8re et mod\u00e9r\u00e9e avec le masitinib\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-10-01T09:57:03+00:00\",\"dateModified\":\"2026-09-29T08:32:54+00:00\",\"description\":\"Le masitinib est positionn\u00e9 dans le traitement de la maladie d'Alzheimer l\u00e9g\u00e8re et mod\u00e9r\u00e9e, pour les patients pr\u00e9sentant des signes de d\u00e9mence\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/maladie-alzheimer\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/maladie-alzheimer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/maladie-alzheimer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pipeline\",\"item\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/pipeline\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Masitinib\",\"item\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Maladie d’Alzheimer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Traitement de la maladie d'Alzheimer l\u00e9g\u00e8re et mod\u00e9r\u00e9e avec le masitinib","description":"Le masitinib est positionn\u00e9 dans le traitement de la maladie d'Alzheimer l\u00e9g\u00e8re et mod\u00e9r\u00e9e, pour les patients pr\u00e9sentant des signes de d\u00e9mence","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Maladie d'Alzheimer","og_description":"Le masitinib est positionn\u00e9 dans le traitement de la maladie d'Alzheimer l\u00e9g\u00e8re et mod\u00e9r\u00e9e, pour les patients pr\u00e9sentant des signes de d\u00e9mence","og_url":"https:\/\/ab-science.excalibra.com\/fr\/pipeline\/masitinib-apercu\/maladie-alzheimer\/","og_site_name":"AB Science","article_modified_time":"2026-09-29T08:32:54+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ab-science.excalibra.com\/fr\/pipeline\/masitinib-apercu\/maladie-alzheimer\/","url":"https:\/\/ab-science.excalibra.com\/fr\/pipeline\/masitinib-apercu\/maladie-alzheimer\/","name":"Traitement de la maladie d'Alzheimer l\u00e9g\u00e8re et mod\u00e9r\u00e9e avec le masitinib","isPartOf":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/#website"},"datePublished":"2020-10-01T09:57:03+00:00","dateModified":"2026-09-29T08:32:54+00:00","description":"Le masitinib est positionn\u00e9 dans le traitement de la maladie d'Alzheimer l\u00e9g\u00e8re et mod\u00e9r\u00e9e, pour les patients pr\u00e9sentant des signes de d\u00e9mence","breadcrumb":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/pipeline\/masitinib-apercu\/maladie-alzheimer\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ab-science.excalibra.com\/fr\/pipeline\/masitinib-apercu\/maladie-alzheimer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ab-science.excalibra.com\/fr\/pipeline\/masitinib-apercu\/maladie-alzheimer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ab-science.excalibra.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Pipeline","item":"https:\/\/ab-science.excalibra.com\/fr\/pipeline\/"},{"@type":"ListItem","position":3,"name":"Masitinib","item":"https:\/\/ab-science.excalibra.com\/fr\/pipeline\/masitinib-apercu\/"},{"@type":"ListItem","position":4,"name":"Maladie d’Alzheimer"}]},{"@type":"WebSite","@id":"https:\/\/ab-science.excalibra.com\/fr\/#website","url":"https:\/\/ab-science.excalibra.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ab-science.excalibra.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ab-science.excalibra.com\/fr\/#organization","name":"AB Science","url":"https:\/\/ab-science.excalibra.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ab-science.excalibra.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]}]}},"_links":{"self":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/3720","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/comments?post=3720"}],"version-history":[{"count":7,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/3720\/revisions"}],"predecessor-version":[{"id":11839,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/3720\/revisions\/11839"}],"up":[{"embeddable":true,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/3763"}],"wp:attachment":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/media?parent=3720"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}